Omeros Q3 net revenue rises 26% on YARTEMLEA sales

By Reuters News


Overview

  • US biotechnology firm's Q3 net revenue rose 26% sequentially on YARTEMLEA sales growth

  • Company posted GAAP net loss due to non-cash loss on convertible notes; reported non-GAAP adjusted net income

  • Omeros repurchased $30.5 mln of 2029 Notes, reducing interest obligations and potential share dilution


Outlook

  • Company says YARTEMLEA revenues continue to grow into the fourth quarter

  • Omeros expects to initiate clinical studies for YARTEMLEA in ARDS and TA-TMA prevention in late 2026 or early 2027

  • Company anticipates near-term milestone payments from Novo related to zaltenibart development


Result Drivers

  • YARTEMLEA SALES GROWTH - Co said higher sales were driven by expanded customer base and increased outpatient use of YARTEMLEA

  • 340B PARTICIPATION - Co said higher purchases by 340B entities contributed to increased gross-to-net adjustment and supported outpatient utilization goals

  • FIELD EDUCATION AND REIMBURSEMENT - Co said investments in field education and new Medicare reimbursement advantages are supporting continued sales momentum


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

$0.79

Q3 Net Loss

$57.40 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Omeros Corporation is $33.00, about 88.7% above its November 13 closing price of $17.49

  • The stock recently traded at 31 times the next 12-month earnings vs. a P/E of 397 three months ago


Reuters Recommended Reads

  • Nov 16 - ALX Oncology Q3 net loss per share narrows

  • Nov 16 - Moleculin Biotech Q3 net loss narrows as MIRACLE trial advances

  • Nov 16 - AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.